Hormonal Therapy for Gynecologic Cancers
Endometrial Cancer
For recurrent or advanced endometrioid endometrial cancer with hormone receptor-positive disease, start with medroxyprogesterone acetate (MPA) 200 mg daily or megestrol acetate (MA) 160 mg daily as first-line hormonal therapy 1, 2. This is the preferred initial systemic treatment for patients with grade 1 or 2 tumors without rapidly progressive disease, offering excellent tolerability with response rates of approximately 25-44% 3, 1, 4.
Patient Selection Criteria
Hormonal therapy is appropriate for:
- Endometrioid histology only - not for papillary serous, clear cell carcinoma, or carcinosarcoma 3
- Estrogen and/or progesterone receptor-positive tumors 1, 2
- Well-differentiated (grade 1-2) tumors 3, 2
- Absence of rapidly progressive or visceral crisis disease 2
- Long disease-free interval predicts better response 3
- Pulmonary metastases respond better than other sites 3
Important caveat: Consider rebiopsy of recurrent disease, as hormone receptor status may differ between primary and metastatic tumors 2.
Sequential Hormonal Therapy Algorithm
First-line: MPA 200 mg/day or MA 160 mg/day 1, 2
- Low-dose MPA (200 mg/day) is superior to high-dose (1000 mg/day) with better response rates (25% vs 15%) and overall survival (11 vs 7 months) 2
- Median progression-free survival: 6.9 months 4
- Patients with positive ER/PR can achieve PFS >12 months, with 2-year PFS of 35% 4
Second-line options after progestin failure:
- Tamoxifen 20-40 mg/day (20% response rate) 3, 1, 2
- Aromatase inhibitors: anastrozole or letrozole (approximately 10% response rate) 2
- Fulvestrant (approximately 10% response rate) 2
Combination regimens:
- Everolimus 10 mg daily + letrozole 2.5 mg daily is recommended for recurrent endometrioid disease 1. This combination achieved 32-40% clinical benefit rate with median PFS of 6 months and median OS of 31 months, superior to MPA/tamoxifen combination (median OS 17 months) 1
- Tamoxifen + MPA combination shows similar efficacy to MPA alone but carries increased risk of grade 4 thromboembolic events 1
Toxicity Profile
Hormonal therapy is remarkably well-tolerated 4, 5:
- Most common adverse event: grade 2 deep vein thrombosis (rare)
- Discontinuation rate due to adverse events: approximately 12%
- No severe adverse events in most series
- Consider concomitant aspirin 100 mg/day for thromboprophylaxis 4
When to Switch to Chemotherapy
Transition to cytotoxic chemotherapy when:
- Disease progression on hormonal therapy 3, 1
- Symptomatic disease requiring rapid response 3
- Grade 2-3 or large-volume disseminated metastases 3
- Rapidly progressive visceral disease 2
Preferred chemotherapy regimen: carboplatin/paclitaxel (40-62% response rate, 13-29 months OS) 1
Estrogen Receptor-Positive Ovarian Cancer
For estrogen receptor-positive endometrioid ovarian cancer, aromatase inhibitors (letrozole 2.5 mg daily) can be used, particularly as maintenance therapy after chemotherapy or between chemotherapy lines 6.
Evidence and Rationale
The evidence for hormonal therapy in ovarian cancer is substantially weaker than for endometrial cancer:
- Aromatase inhibitors have not been adequately assessed in ovarian cancer 6
- Case reports demonstrate prolonged remissions (30 months) with letrozole in ER-positive endometrioid ovarian cancer 6
- Most effective when tumor burden is low after primary chemotherapy 6
- Best used as maintenance therapy between chemotherapy regimens 6
Clinical Application
Appropriate candidates:
- Endometrioid histology with positive ER status
- Low tumor burden after chemotherapy response
- Maintenance setting between chemotherapy lines
- Patients seeking treatment break from cytotoxic therapy
Important distinction: Low-grade serous and low-grade endometrioid ovarian tumors have unclear safety profiles with hormonal therapy 7. The evidence base is insufficient to make strong recommendations for these subtypes.
Monitoring During Hormonal Therapy
For both endometrial and ovarian cancer patients on hormonal therapy:
- Clinical assessment every 3-4 months initially 7
- CA-125 monitoring (for ovarian cancer) 7
- Imaging only if clinically indicated by symptoms or rising tumor markers 7
- Assess for thromboembolic complications
- Monitor quality of life and menopausal symptoms
Critical pitfall: Do not use adjuvant hormonal therapy in early-stage endometrial cancer - it does not improve survival and is not recommended 3, 8, 9.